Embracing Nippon Shinyaku’s Business Philosophy, “Helping people lead healthier, happier lives,” we aspire to be and remain a pharmaceutical company that is capable of constantly offering quality drugs with distinctive features to people with ill health, thus alleviating their suffering and enhancing their well-being.
We strive to do this by concentrating our managerial resources on promoting R&D and maximizing the product value in four fields of focus: urology, hematology, intractable and rare diseases (e.g., pulmonary arterial hypertension [PAH], muscular dystrophy), and gynecology.
In the field of urology, we have a wide variety of products ranging from Eviprostat launched in 1967 for the treatment of benign prostatic hypertrophy to Erleada and Zytiga, both for the treatment of prostate cancer. This is Nippon Shinyaku’s focal field with respect to both sales and R&D because of the company’s rich R&D achievements related to urology and, in particular, lower urinary tract diseases.
Nippon Shinyaku entered the field of hematology in 1971. The company’s Cylocide for treating acute leukemia and Vidaza for treating myelodysplastic syndrome have become therapeutic standards that have been playing an important role in treating hematological cancers. In 2019, the company launched Defitelio for the treatment of sinusoidal obstruction syndrome. This is the only drug that is approved for this indication in Japan, thereby making a significant contribution to the treatment of this disease. In this field of R&D focus, Nippon Shinyaku is expanding the pipeline through R&D for original drugs and in-licensing.
Intractable and rare diseases
Intractable and rare diseases constitute another important focal field for Nippon Shinyaku. The company has targeted R&D for many years and bore fruit as the launch of Uptravi in 2016, which is an original drug for the treatment of PAH. With Adcirca and Opsumit, also indicated for PAH and each of the three drugs with a different mechanism of action, Nippon Shinyaku offers a unique set of treatment solutions. More recent years have seen the launch of Viltepso for the treatment of Duchenne muscular dystrophy (DMD) in Japan and the United States. This is the first nucleic acid drug manufactured in Japan.
Lunabell LD, which contains low-dose estrogen and progesterone, is Japan’s first insurance-covered treatment drug for dysmenorrhea that is associated with endometriosis. Since its launch, this drug has greatly contributed to improving the quality of life of many women with painful menstruation. In this field, Nippon Shinyaku is currently working on the clinical studies of “NS-32” for treating iron deficiency anemia and “NS-580” for treating endometriosis.